Post hoc analysis of phase 3 COPD trials: stability (no moderate/severe exacerbation, no CAT or FEV1 worsening) was reached by 18%-46% of patients; stability at week 28 was linked to 45.7% lower exacerbation risk and 51.7% lower mortality risk afterwards.
Secondary analysis
Singh et al. Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials